Order of amino acids in C-terminal cysteine-containing peptide-based chelators influences cellular processing and biodistribution of 99mTc-labeled recombinant Affibody molecules

Amino Acids

Volumn 42, Issue 5, 2012, Pages 1975-1985

  Altai, Mohamed ^a   Wållberg, Helena ^b   Orlova, Anna ^a   Rosestedt, Maria ^a   Hosseinimehr, Seyed Jalal ^a,c   Tolmachev, Vladimir ^a   Ståhl, Stefan ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Affibody molecule; C terminal cysteine; HER2; Molecular imaging; Peptide based chelator; Technetium 99m

Indexed keywords

AMINO ACID; CHELATING AGENT; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RECOMBINANT AFFIBODY; RECOMBINANT PROTEIN; TECHNETIUM 99M; UNCLASSIFIED DRUG;

AMINO ACID COMPOSITION; AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOACCUMULATION; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ISOTOPE LABELING; KIDNEY; LIVER; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY;

AMINO ACIDS; ANIMALS; CHELATING AGENTS; CYSTEINE; HUMANS; ISOTOPE LABELING; MICE; MOLECULAR IMAGING; PEPTIDES; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 84862763098     PISSN: 09394451     EISSN: 14382199     Source Type: Journal    
DOI: 10.1007/s00726-011-0927-x     Document Type: Article

References (34)

1. Ahlgren S, Tolmachev V (2010) Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol 11:581-589
2. Ahlgren S, Orlova A, Rosik D, Sandström M, Sjöberg A, Baastrup B, Widmark O, Fant G, Feldwisch J, Tolmachev V (2008) Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant Affibody molecules. Bioconjug Chem 19:235-243 (Pubitemid 351213855)
3. Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V (2009) Targeting of HER2-expressing tumors using a site-specifically 99mTc-labeled recombinant Affibody molecule ZHER2:2395 with C-terminal engineered cysteine. J Nucl Med 50:781-789
4. Ahlgren S, Orlova A, Wållberg H, Hansson M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V, Feldwisch J (2010a) Targeting of HER2-expressing tumors using 111In-ABY-025, a second generation Affibody molecule with a fundamentally re-engineered scaffold. J Nucl Med 51:1131-1138
5. Ahlgren S, Andersson K, Tolmachev V (2010b) Kit formulation for 99mTc-labeling of recombinant anti-HER2 Affibody molecules with a C-terminally engineered cysteine. Nucl Med Biol 37:539-546
6. Baum RP, Prasad V, Müller D, Schuchardt C, Orlova A, Wennborg A, Tolmachev V, Feldwisch J (2010) Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled Affibody. J Nucl Med 51:892-897
7. Britz-Cunningham SH, Adelstein SJ (2003) Molecular targeting with radionuclides: state of the science. J Nucl Med 44:1945-1961 (Pubitemid 40022141)
8. Cameron DA, Stein S (2008) Drug insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer. Nat Clin Pract Oncol 5:512-520
9. Chang HR (2010) Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 116:2856-2867
10. Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505-516 (Pubitemid 44036456)
11. Ekblad T, Tran T, Orlova A et al (2008) Development and preclinical characterisation of 99mTc-labelled Affibody molecules with reduced renal uptake. Eur J Nucl Med Mol Imaging 35:2245-2255
12. Ekblad T, Orlova A, Feldwisch J, Wennborg A, Eriksson Karlström A, Tolmachev V (2009) Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules. Bioorg Med Chem Lett 19:3912-3914
13. Engfeldt T, Orlova A, Tran T et al (2007a) Imaging of HER2- expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence. Eur J Nucl Med Mol Imaging 34:722-733 (Pubitemid 46669355)
14. Engfeldt T, Tran T, Orlova A, Widström Ch, Eriksson Karlström A, Tolmachev V (2007b) 99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule. Eur J Nucl Med Mol Imaging 34:1843-1853 (Pubitemid 47599054)
15. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184
16. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY (2010) Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 584:2670-2680
17. Mankoff DA (2009) Molecular imaging to select cancer therapy and evaluate treatment response. Q J Nucl Med Mol Imaging 53:181-192
18. Miao Z, Levi J, Cheng Z (2010) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids. doi: 10.1007/s00726-010-0503-9
19. Nygren PA (2008) Alternative binding proteins: affibody binding proteins developed from a small three-helix bundle scaffold. FEBS J 275:2668-2676
20. Orlova A, Tolmachev V, Pehrson R, Lindborg M, Tran T, Sandström M, Nilsson FY, Wennborg A, Abrahmsén L, Feldwisch J (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178-2186 (Pubitemid 46424237)
21. Orlova A, Magnusson M, Eriksson T, Nilsson M, Larsson B, Höiden- Guthenberg I, Widström C, Carlsson J, Tolmachev V, Ståhl S, Nilsson F (2006) Tumor imaging using a picomolar affinity HER2 binding Affibody molecule. Cancer Res 66:4339-4348
22. Tolmachev V (2008) Imaging of HER-2 overexpression in tumors for guiding therapy. Curr Pharm Des 14:2999-3011
23. Tolmachev V, Nilsson FY, Widström C, Andersson K, Rosik D, Gedda L, Wennborg A, Orlova A (2006) 111In-benzyl-DTPAZHER2: 342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med 47:846-853 (Pubitemid 46772889)
24. Tolmachev V, Stone-Elander S, Orlova A (2010a) Current approaches to the use of radiolabeled tyrosine kinase-targeting drugs for patient stratification and treatment response monitoring: prospects and pitfalls. Lancet Oncol 11:992-1000
25. Tolmachev V, Hofström C, Malmberg J et al (2010b) HEHEHEtagged affibody molecule may be purified by IMAC, is conveniently labeled with [99(m)Tc(CO)3](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug Chem 21:2013-2022
26. Tolmachev V, Velikyan I, Sandström M, Orlova A (2010c) A HER2- binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging 37:1356-1367
27. Tran T, Engfeldt T, Orlova A et al (2007a) In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumortargeting Affibody molecules. Biocojug Chem 18:549-558 (Pubitemid 46493528)
28. Tran T, Engfeldt T, Orlova A et al (2007b) 99mTc-maEEEZHER2: 342, an Affibody molecule-based tracer for detection of HER2-expression in malignant tumors. Bioconjug Chem 18:1956-1964 (Pubitemid 350219996)
29. 99mTclabeled anti-HER2. Bioconjug Chem 19:2568-2576
30. Tran TA, Rosik D, Abrahmsén L et al (2009) Design, synthesis and biological evaluation of a HER2-specific affibody molecule for molecular imaging. Eur J Nucl Med Mol Imaging 36:1864-1873
31. Wållberg H, Orlova A (2008) Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm 23:435-442
32. Wållberg H, Ahlgren S, Widström C, Orlova A (2010) Evaluation of the radiocobalt-labeled [MMA-DOTA-Cys61]-Z HER2:2395(- Cys) affibody molecule for targeting of HER2-expressing tumors. Mol Imaging Biol 12:54-62
33. Wållberg H, Orlova A, Altai M, Widström C, Hosseinimehr SJ, Malmberg J, Ståhl S, Tolmachev V (2011a) Molecular design and optimization of 99mTc-labeled recombinant affibody molecules improves their biodistribution and imaging properties. J Nucl Med 52:461-469
34. Wållberg H, Löfdahl PÅ, Tschapalda K, Uhlén M, Tolmachev V, Nygren PÅ , Ståhl S (2011b) Affinity recovery of eight HER2- binding affibody variants using an anti-idiotypic affibody ligand. Protein Exp Purif 76:127-135